Victory Capital Management Inc. Has $69.11 Million Stock Holdings in Pediatrix Medical Group, Inc. $MD

Victory Capital Management Inc. grew its holdings in Pediatrix Medical Group, Inc. (NYSE:MD) by 30.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,126,207 shares of the company’s stock after acquiring an additional 968,553 shares during the quarter. Victory Capital Management Inc. owned 4.80% of Pediatrix Medical Group worth $69,114,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Smartleaf Asset Management LLC boosted its holdings in shares of Pediatrix Medical Group by 10.6% in the 3rd quarter. Smartleaf Asset Management LLC now owns 6,250 shares of the company’s stock valued at $101,000 after buying an additional 601 shares during the last quarter. PNC Financial Services Group Inc. lifted its position in Pediatrix Medical Group by 4.5% during the third quarter. PNC Financial Services Group Inc. now owns 14,525 shares of the company’s stock worth $243,000 after acquiring an additional 631 shares during the last quarter. Amalgamated Bank boosted its stake in Pediatrix Medical Group by 3.5% in the 3rd quarter. Amalgamated Bank now owns 24,891 shares of the company’s stock valued at $417,000 after purchasing an additional 831 shares during the period. New York State Common Retirement Fund grew its stake in shares of Pediatrix Medical Group by 1.7% in the second quarter. New York State Common Retirement Fund now owns 62,245 shares of the company’s stock valued at $893,000 after acquiring an additional 1,034 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC raised its position in shares of Pediatrix Medical Group by 10.0% in the third quarter. Vanguard Personalized Indexing Management LLC now owns 11,977 shares of the company’s stock valued at $201,000 after buying an additional 1,092 shares in the last quarter. 97.71% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

MD has been the topic of a number of analyst reports. Zacks Research downgraded shares of Pediatrix Medical Group from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 23rd. UBS Group cut their price target on Pediatrix Medical Group from $23.00 to $22.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 24th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Pediatrix Medical Group in a research report on Monday, December 29th. Deutsche Bank Aktiengesellschaft set a $19.00 price target on shares of Pediatrix Medical Group in a research report on Friday, February 20th. Finally, Truist Financial lowered their price objective on shares of Pediatrix Medical Group from $24.00 to $21.00 and set a “hold” rating on the stock in a research report on Thursday, February 19th. One equities research analyst has rated the stock with a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $19.80.

Pediatrix Medical Group Price Performance

Shares of NYSE:MD opened at $19.29 on Friday. The company has a quick ratio of 1.66, a current ratio of 1.66 and a debt-to-equity ratio of 0.66. The stock has a market cap of $1.60 billion, a PE ratio of 9.94 and a beta of 0.79. The company’s fifty day moving average is $21.16 and its 200 day moving average is $19.88. Pediatrix Medical Group, Inc. has a 52 week low of $11.84 and a 52 week high of $24.99.

Pediatrix Medical Group (NYSE:MD) last posted its earnings results on Thursday, February 19th. The company reported $0.50 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.53 by ($0.03). The business had revenue of $493.77 million for the quarter, compared to analysts’ expectations of $486.23 million. Pediatrix Medical Group had a net margin of 8.64% and a return on equity of 19.59%. Pediatrix Medical Group’s quarterly revenue was down 1.7% on a year-over-year basis. During the same period last year, the firm posted $0.51 earnings per share. Research analysts anticipate that Pediatrix Medical Group, Inc. will post 1.38 earnings per share for the current year.

Insider Buying and Selling

In other Pediatrix Medical Group news, CEO Mark S. Ordan sold 23,000 shares of the firm’s stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $22.41, for a total transaction of $515,430.00. Following the completion of the sale, the chief executive officer directly owned 302,805 shares in the company, valued at approximately $6,785,860.05. This trade represents a 7.06% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.90% of the company’s stock.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.